Marc d'Anjou

Marc has worked at bluebird bio since 2017 in MSAT and Regulatory CMC roles supporting the development and regulatory approval of 4 cell-based gene therapies in oncology and rare disease. In his current role as Sr. Director of Reg-CMC, he focuses on the CMC elements of the BLA for LYFGENIA, a transformative LVV-based autologous gene therapy for Sickle Cell Disease. Prior to bluebird bio, he held roles in MSAT and biologics process development at BMS, Merck and GlycoFi. Marc holds an M.Sc.(Eng). from Queen's University in Kingston, Ontario.